Alerta

JUNCTION OPENER PROTEIN AND NANOPARTICLE COMPOSITIONS AND USES THEREOF

Absstract of: WO2025081013A1

The disclosures provides compositions comprising nanoparticles and a junction opener protein; and nanoparticles comprising one or more bioactive agents and a junction opener protein that is conjugated to the surface of the nanoparticles. Various bioactive agents are described, such as squalene, squalane, and dehydroisosqualene, among others. Various nanoparticle compositions are provided, including lipid carriers comprising a hydrophobic core. Methods for treating a subject with cancer by administering the compositions provided herein are also described.

PEPTIDE HYDROGELS AND THEIR USE FOR SKELETAL MUSCLE REGENERATION AS STIMULATORS OF MYOBLAST MIGRATION AND FUSION

Absstract of: EP4792824A1

0001 A peptide-based hydrogel for skeletal muscle regeneration, comprising: a) a self-assembling RADA16-I peptide forming a nanofibrous hydrogel matrix; and b) at least one bioactive peptide selected from: peptide fragment of stromal cell-derived factor 1 (SDF-1): SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, or peptide fragment of interleukin-4 (IL-4): SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, wherein the bioactive peptide is covalently linked to the RADA16-I sequence via a matrix metalloproteinase (MMPs) cleavable peptide linker and wherein cleavage of the linker by an MMPs results in controlled, localized release of the bioactive peptide in the microenvironment of regenerating muscle tissue.

GLUTAMIC ACID-BASED LIPIDS, LIPID NANOPARTICLE CONTAINING GLUTAMIC ACID-BASED LIPIDS, AND FORMULATIONS THEREOF

Absstract of: WO2025076625A1

Provided is a glutamic or glutaric acid-based ionizable lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 20 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 10 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. In some embodiments, the ionizable lipid compound is a glutamic acid-based ionizable lipid compound.

IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY

Absstract of: WO2025077836A1

Provided herein is novel ionizable cationic lipid compound that can be assembled with other helper lipids, such as phospholipids, structural lipids, and polymer conjugated lipids capable of reducing aggregation, to form lipid nanoparticles for delivery of therapeutic RNA both in vitro and in vivo. These compounds contain a thiourea group in the linker between the lipid group and the head group (-NRc-C(S)-NRd-).

ENGINEERING ANTIGEN-SPECIFIC T CELLS FOR CAR T CELL THERAPY BY ANTIGEN-PRESENTING LIPID NANOPARTICLES

Absstract of: WO2025081194A2

Antigen-presenting nanoparticles and methods of engineering CAR T cells and treating and/or preventing cancer using the same.

LIPID NANOPARTICLES

Absstract of: WO2025080945A1

The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.

MEANS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE EFFECTOR CELLS

Absstract of: WO2025078699A1

The current disclosure relates to targeted delivery of agents to T cells and/or NK cells. Highly suitable targeting domains were meticulously identified that allow for an agent, such as DNA and/or RNA, to be delivered to T cells and/or NK cells. As shown, when lipid nanoparticles were provided with such a targeting domain, nucleic acid comprised in said lipid nanoparticles was highly efficiently and specifically delivered. This allows for engineering of T cells and/or NK cells, highly useful in medical treatments for cancer.

LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF

Absstract of: WO2025080565A1

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF

Absstract of: WO2025080209A1

There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein AR comprises a unit from a poly(amino acid); R1 and R2 are each independently a hydrophobic group; R3, R4, and R5 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7 is –H or –C(=O)R8, wherein R8 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; m ≥ 1; and n ≥ 1.

CARRIER CAPABLE OF TARGETING CELL AT SUBSET LEVEL AND METHOD FOR PRODUCING SAME

Absstract of: EP4792807A1

0001 A problem to be solved by the present invention is to provide a carrier capable of being selectively delivered to cells at a subset level, which has not yet been realized by conventional art, and to provide a method for producing the carrier. The present invention relates to a carrier for selective delivery to a target cell having multiple types of target receptors on its surface, the carrier having multiple types of ligands, wherein each type of ligand binds to one of the multiple types of target receptors, wherein the carrier is taken up by the target cell that has all the multiple types of target receptors, but is not taken up by a cell that lacks at least one of the multiple types of target receptors; a method for producing the carrier; and the like.

IMMUNE CELL TARGETED DELIVERY VEHICLES AND METHODS OF USE THEREOF

Absstract of: WO2025080672A1

The present invention relates to methods and compositions comprising a delivery vehicle conjugated to a chemokine or cytokine ligand, wherein the delivery vehicle comprises at least one agent, and wherein the targeting domain specifically binds to the surface of a target immune cell. The invention also relates to methods for treating or preventing diseases and disorders, including cancers, infectious diseases, and immunological disorders, using the described delivery vehicle for delivery of a therapeutic agent.

IONIZABLE LIPIDS FOR IMPROVED MRNA DELIVERY

Absstract of: WO2025080867A1

Provided herein are ionizable cationic lipids and lipid nanoparticle compositions comprising a lipid component comprising the same. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.

LIVER ASIALOGLYCOPROTEIN RECEPTOR TARGETED LIPID AND USES THEREOF

Absstract of: WO2025080572A1

A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.

CARBONATE CONTAINING LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

Absstract of: EP4793267A1

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

POLYMERIC NANOCARRIERS FOR DELAYING ONSET OF TYPE I DIABETES

Absstract of: WO2025081185A1

Disclosed herein are methods for delaying the onset of type I diabetes and preventing nosocomial infections by administering PEG-b-PPS nanocarriers loaded with rapamycin. This invention aims to reduce the frequency of visits to a transfusion clinic, reduce the costs of treatments, and reduce adverse side effects, without reducing the effects of the islet transplant. This is accomplished by the use of a nanocarrier which targets treatment to the desired location.

用于治疗结直肠癌和继发性肺转移的RNA-SN-38缀合物

Absstract of: WO2025097049A1

Disclosed herein are compositions and methods for CMC production of RNA therapeutic complexes (nanostructures) that contain SN-38 (7-Ethyl-10-hydroxycamptothecin) and/or Irinotecan. In particular, disclosed herein is an RNA nanoparticle having at least three synthetic RNA nucleotides coupled to each other, wherein the at least three synthetic RNA oligonucleotides form a central ore domain and at least three double-stranded arms arranged around the core domain and extending away from the central core domain, wherein at least one of the three double-stranded arms is conjugated with Irinotecan and/or SN-38 with an esterbond that is cleavable by esterase in cancer tissue or cancer cells.

用于药物递送的纳米颗粒组合物

Absstract of: WO2025143871A1

The present invention relates to a composition for drug delivery and a preparation method thereof and, more specifically, to: a composition for drug delivery in which a drug is encapsulated inside a nanoparticle structure formed by a specific polymer and a cationic compound; and a preparation method thereof.

一种纳米姜黄素复合物及其制备方法和应用

Absstract of: CN122582125A

本发明提供了一种纳米姜黄素复合物及其制备方法和应用，属于生物医药技术领域。本发明提供的纳米姜黄素复合物中，插入功能性小分子肽段的神经元细胞膜作为外壳，内部包裹负载姜黄素的纳米粒子，能够显著提高姜黄素的溶解度和稳定性，促进其穿过血脑屏障并在脑组织中富集，同时有效抑制α‑突触核蛋白的磷酸化和异常聚集，从而在体内外模型中均表现出对长期低氧诱导的慢性神经损伤的显著保护作用。本发明为低氧相关神经系统疾病的预防和治疗提供了新的药物策略和理论依据。

piR-1873在制备心肌梗死诊断产品或治疗药物中的应用

Absstract of: CN122588230A

本发明公开了一种piR‑1873在制备心肌梗死诊断产品或治疗药物中的应用，本发明中piR‑1873在MI患者、MI动物模型及H2O2诱导心肌细胞中均显著下调，受试者工作特征（ROC）曲线分析显示其具有较高的敏感性和特异性，进而其具有潜在的早期诊断价值，此外，piR‑1873可通过负向调控USP2并抑制RIP1/RIP3/MLKL介导的坏死性凋亡，从而保护心肌细胞免受损伤，为心肌梗死的治疗提供了新的精准干预策略。

可电离聚合物、聚合物脂质杂化纳米颗粒的制备及其应用

Absstract of: CN122587206A

本申请公开了可电离聚合物、聚合物脂质杂化纳米颗粒及应用，属于生物医药技术领域。该可电离聚合物具有式（I）所述的分子结构：，其中，n为1‑50的整数。通过模块化结构设计实现在不同的pH条件下调控电荷状态，完成对核酸的高效包载与释放。同时公开的聚合物脂质杂化纳米颗粒可表现出更优的体内递送能力、组织表达效果以及局部表达能力，从而兼具多种给药场景下的应用潜力。

一种基于氟化壳聚糖的纳米载体PTX-FP@FCS-NPs的制备方法及应用

Absstract of: CN122582120A

本发明提供了一种基于氟化壳聚糖的纳米载体PTX‑FP@FCS‑NPs的制备方法，该方法为：合成氟化壳聚糖，将吐温80和氟化壳聚糖溶解于乙酸水溶液中，搅拌后，得到混合溶液，再将溶解后的5,10,15,20‑四(3,5‑双(三氟甲基)苯基)卟啉和紫杉醇加入混合溶液中，搅拌、离心，取沉淀物质，用蒸馏水洗涤沉淀物质后，得到基于氟化壳聚糖的纳米载体PTX‑FP@FCS‑NPs。本发明还提供了上述基于氟化壳聚糖的纳米载体PTX‑FP@FCS‑NPs的应用，用于制备改善肝细胞癌的药物，且与激光照射联合应用。本发明通过氟化修饰策略，构建了兼具清晰19F MRI/FLI双模态成像、pH/激光双响应药物释放特性以及高效共载紫杉醇和卟啉能力的纳米载体，该纳米载体在激光刺激下通过多机制协同作用，有效抑制肿瘤生长，且具有良好的生物安全性。

由支架部分制备的脂质缀合物

Absstract of: JP2025060670A

To provide a drug-lipid conjugate that allows a broader range of drugs to be easily incorporated into a drug delivery medium.SOLUTION: For example, a drug-lipid conjugate represented by the following formula is illustrated.SELECTED DRAWING: None

一种用于递送蛋白的工程化间充质干细胞外泌体及其制备方法和用途

Absstract of: CN122588010A

本发明属于生物医药及纳米药物递送技术领域，具体涉及一种用于递送蛋白的工程化间充质干细胞外泌体及其制备方法和用途。所述外泌体由含有外源表达盒的间充质干细胞分泌产生；所述表达盒包括由同一启动子驱动且顺序连接的BDNF编码序列（其编码的氨基酸序列如SEQ ID NO:1所示）、T2A序列（其编码的氨基酸序列如SEQ ID NO:2所示）以及RVG‑Lamp2b融合蛋白编码序列；所述外泌体包括：富集于所述外泌体内腔的、具有独立天然构象的BDNF蛋白。本申请成功克服血脑屏障限制：通过RVG肽介导的受体途径，实现工程化外泌体高效跨越血脑屏障并进入脑组织。本申请用于高效负载脑源性神经营养因子并具有跨越血脑屏障的靶向能力，在重度抑郁症等中枢神经系统疾病治疗中具有应用前景。

葡聚糖包覆的锰掺杂硫化钼纳米花/cGAMP纳米复合物及其制备方法与应用

Absstract of: CN122582121A

本申请涉及生物医药及医疗器械领域，公开了葡聚糖包覆的锰掺杂硫化钼纳米花/cGAMP纳米复合物及其制备方法与应用。所述纳米复合物为核‑壳结构，包括：Mn‑MoS2纳米花内核；cGAMP负载层，负载于所述Mn‑MoS2纳米花内核表面；以及葡聚糖涂层，包覆于所述cGAMP负载层表面。本申请采用具有压电/声响应特性的Mn–MoS2纳米花作为核心，并在外界超声刺激下产生压电极化与电荷分离，诱导或放大局部ROS生成。生物膜的EPS基质与细菌膜/壁对氧化应激高度敏感，ROS可对多糖链、蛋白与脂质产生氧化切断或结构破坏。

一种多活性物共包封仿生纳米囊泡及其制备方法

Nº publicación: CN122582123A 18/08/2026

Applicant:

四川晨曦瑞恒生物科技有限公司

Absstract of: CN122582123A

本发明公开了一种多活性物共包封仿生纳米囊泡及其制备方法，属于生物医药技术领域。一种多活性物共包封仿生纳米囊泡，包括仿生纳米囊泡载体以及包封于所述仿生纳米囊泡载体内部的活性物体系；本发明采用氢化卵磷脂、植物鞘氨醇及植物固醇的三元脂质复配体系自组装形成仿生纳米囊泡载体，相较于传统“磷脂+胆固醇”二元脂质体，植物鞘氨醇的长链饱和结构嵌入磷脂分子间隙，与植物固醇协同发挥“双向流动性调节”作用，使脂质双层膜的致密性与机械强度显著增强。经30天常温储存试验验证，本发明囊泡的活性物渗漏率较传统脂质体降低72%以上，粒径变化率低于7%，有效解决了普通脂质体易聚集融合、内容物泄漏、货架期短的技术难题。